PKMYT1 inhibitor therapeutic - Acrivon Therapeutics
Latest Information Update: 30 Jan 2023
At a glance
- Originator Acrivon Therapeutics
- Class Antineoplastics
- Mechanism of Action PKMYT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Dec 2022 PKMYT1 inhibitor therapeutic - Acrivon Therapeutics is available for licensing as of 27 Dec 2022. https://acrivon.com/
- 27 Dec 2022 Preclinical trials in Cancer in USA (unspecified route) Before December 2022 (Acrivon Therapeutics pipeline, December 2022)